Erica Heagy
Family · Anchorage, AKNPI 1134218720
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 33.6% of the total. Reporting peaked in 2024 at $134,697 and has fallen 98.2% since, to $2,423 in 2025. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $464.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$84K
- AbbVie$46K
- Lilly USA, LLC$44K
- Janssen Scientific Affairs, LLC$21K
- Regeneron Healthcare Solutions, Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- plus $18K from 7 others
What the payments were for
- Consulting fees$12,6835%
- Speaking & faculty fees$147,92659%
- Travel & lodging$78,24331%
- Food & beverage$10,0884%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 123 | $83,634 |
| AbbVie | 123 | $46,234 |
| Lilly USA, LLC | 103 | $44,019 |
| Janssen Scientific Affairs, LLC | 39 | $21,183 |
| Regeneron Healthcare Solutions, Inc. | 61 | $20,860 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $14,651 |
| E.r. Squibb & Sons, L.L.C. | 9 | $5,898 |
| Sanofi | 8 | $5,808 |
| Eli Lilly | 11 | $4,841 |
| Celltrion USA Inc. | 1 | $1,020 |
| Bristol Myers Squibb | 9 | $711 |
| Pfizer | 2 | $144 |
| Gilead | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$249,046 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 27 | $231,812 |
| ZenpepLipase/Protease/Amylase | 11 | $89,553 |
| XifaxanRifaximin | 28 | $83,350 |
| CreonLipase/Protease/Amylase | 29 | $54,541 |
| Mesalamine | 58 | $35,708 |
| LinzessLinaclotide | 19 | $26,881 |
| Dexlansoprazole DrDexlansoprazole | 22 | $12,611 |
| AprisoMesalamine | 17 | $11,954 |
| Budesonide DrBudesonide | 32 | $6,087 |
| Sucralfate | 40 | $4,399 |
| Pantoprazole Sodium | 246 | $3,299 |
| Ursodiol | 24 | $2,307 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $2,299 |
| Esomeprazole Magnesium | 19 | $2,292 |
| Budesonide EcBudesonide | 14 | $1,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Creon, Linzess | $46,234 | $313,23475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 315 family providers in Alaska.
Other family in Anchorage
- Trisha KernodleAnchorage$60K
- Marisha DietersAnchorage$6K
- Christine HooverAnchorage$6K
- Leigh KeeferAnchorage$5K
- Sara GeraciAnchorage$4K
- Christine SaganAnchorage$4K
- Bethany BuchananAnchorage$4K
- Natasha SherrillAnchorage$4K
- Katherine HardyAnchorage$3K
- Andrea BirchAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.